Skip to content
Stock futures rose Wednesday evening as investors awaited a deluge of earnings results set for release Thursday morning, along with new economic data on the state of the consumer and labor market as the pandemic continues....
John Grace, Founder and President of Investor’s Advantage Corp., joins The Final Round to highlight what bank earnings means for investors and his outlook for the second half of 2020.
...
Biogen Inc (NASDAQ: BIIB) is caught in more than one legal wrangle with generic companies over patents related to its key multiple sclerosis drug Tecfidera, which was approved by the FDA in March 2013.The Biogen Analyst: Morgan Stanley analyst Matthew Harrison has an Underweight rating on Biogen with a $263 price target. The Biogen Thesis: Two legal catalysts in the coming weeks will help determine when a generic version of Tecfidera may be launched and by which companies, Harrison said in a Wednesday note. (See his track record here.)These catalysts are significant for Biogen, as Tecfidera is estimated to rake in about 30% of the company's total sales in 2020, the analyst said. If a generic is launched, Biogen stands to lose significant Tecfidera market share, and the price of the drug is likely to erode steeply within the first year of generic market entry, he said.Vumerity, Biogen's prodrug version of...
Twitter’s thin veil of security went into full meltdown at 19:00 UTC on Wednesday. Within hours, even Barack Obama’s account was compromised....
